🚨 #ISC26 delivered BIG for stroke care. Multiple practice-important and promising trials across thrombosis, reperfusion, EVT, ICH, and neuroprotection 🏥🧠👇
🔹 OCEANIC-STROKE – Positive phase III: FXIa inhibition with asundexian reduced ischemic stroke in patients with non-cardioembolic stroke or high-risk TIA on antiplatelet therapy without increased major bleeding
🔹 OPTION – In patients with salvageable tissue, tenecteplase (4.5–24h) significantly improved 90-day excellent outcomes with higher sICH (2.8% vs 0%)
🔹 CHOICE-2 – Largest phase III trial of IA alteplase after successful EVT: higher excellent outcomes (mRS 0–1), no increase in sICH, NNT ≈ 7
🔹 FASTEST – rFVIIa for spontaneous ICH: promising early results in spot sign–positive patients treated <90 min
🔹 LAIS – Loberamisal (dual-target neuroprotection) within 48h for AIS (NIHSS 7–20): 13% absolute increase in excellent functional outcomes at 90 days
🔹 DISTALS – Tigertriever for distal occlusions: higher successful reperfusion at 24h without increased sICH
🔹 ORIENTA-MeVO – EVT for MeVO improved 90-day functional outcomes without excess sICH in a Chinese population
The stroke playbook is evolving in real time. 🔥
#Stroke #ISC26 #VascularNeurology #EVT #Tenecteplase #ICH #ClinicalTrials #AHAScience #StrokeResearch @StrokeAHA_ASA @AHAScience 🧠
English
